The effect of air cooling pain relief on protoporphyrin IX photobleaching and clinical efficacy during dermatological photodynamic therapy

Journal of Photochemistry and Photobiology B: Biology

Volumn 103, Issue 1, 2011, Pages 1-7

  Tyrrell, J ^a   Campbell, S M ^a   Curnow, A ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Air cooling device; Dermatology; Methyl aminolevulinate (MAL); Non invasive fluorescence imaging; Pain relief; Photodynamic therapy (PDT)

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; PHOTOSENSITIZING AGENT; PROTOPORPHYRIN;

ACTINIC KERATOSIS; ADULT; AGED; ANALGESIA; ARTICLE; BASAL CELL CARCINOMA; BLEACHING; BOWEN DISEASE; CONTROL GROUP; CONTROLLED STUDY; COOLING; DERMATOLOGY; DEVICE; FEMALE; HUMAN; IRRADIATION; LIGHT; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN DEFECT; TREATMENT OUTCOME;

AGED; AIR; AIR CONDITIONING; COLD TEMPERATURE; FEMALE; HUMANS; LIGHT; MALE; OXYGEN; PAIN; PHOTOBLEACHING; PHOTOCHEMOTHERAPY; PROTOPORPHYRINS; REACTIVE OXYGEN SPECIES; RETROSPECTIVE STUDIES; SKIN DISEASES; TREATMENT OUTCOME; VASOCONSTRICTION;

EID: 79952183504     PISSN: 10111344     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2010.12.011     Document Type: Article

References (59)

1. Q. Peng, K. Berg, J. Moan, M. Kongshaug, J.M. Nesland, 5-Aminolevulinic acidbased photodynamic therapy: principles and experimental research, Photochem. Photobiol. 65 (2) (1997) 235-251.
2. B.W. Henderson, T.J. Dougherty, How does photodynamic therapy work?, Photochem Photobiol. 55 (1) (1992) 145-157.
3. D. Nowis, M. Makowski, T. Stoklosa, M. Legat, T. Issat, J. Golab, Direct tumor damage mechanisms of photodynamic therapy, Acta Biochim. Pol. 52 (2) (2005) 339-352.
4. C.A. Morton, Methyl aminolevulinate (Metvix) photodynamic therapy - practical pearls, J. Dermatol. Treat. 14 (Suppl. 3) (2003) 23-26.
5. P. Foley, Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy, J. Dermatol. Treat. 14 (Suppl. 3) (2003) 15-22.
6. J.A. Neville, E. Welch, D.J. Leffell, Management of nonmelanoma skin cancer in 2007, Nat. Clin. Pract. Oncol. 4 (8) (2007) 462-469.
7. R. Szeimies, S. Ibbotson, D. Murrell, D. Rubel, Y. Frambach, D. de Berker, et al., A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up, J. Eur. Acad. Dermatol. Venereol. 22 (11) (2008) 1302-1311.
8. L.R. Braathen, R.M. Szeimies, N. Basset-Seguin, R. Bissonnette, P. Foley, D. Pariser, et al., Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus, Int. Soc. Photodyn. Ther. Dermatol., 2005
9. J. Am. Acad. Dermatol. 56 (1) (2007) 125-143.
10. E.P. Tierney, M.J. Eide, G. Jacobsen, D. Ozog, Photodynamic therapy for actinic keratoses: survey of patient perceptions of treatment satisfaction and outcomes, J. Cosmet. Laser Ther. 10 (2) (2008) 81-86.
11. I. Wang, N. Bendsoe, C.A. Klinteberg, A.M. Enejder, S. Andersson-Engels, S. Svanberg, et al., Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial, Br. J. Dermatol. 144 (4) (2001) 832-840.
12. R.M. Szeimies, S. Ibbotson, D.F. Murrell, D. Rubel, Y. Frambach, D. de Berker, et al., A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up, J. Eur. Acad. Dermatol. Venereol. 22 (11) (2008) 1302-1311.
13. Q. Peng, T. Warloe, K. Berg, J. Moan, M. Kongshaug, K.E. Giercksky, et al., 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges, Cancer 79 (12) (1997) 2282-2308.
14. J. Moan, V. Iani, L.W. Ma, Choice of the proper wavelength for photochemotherapy, SPIE, 1996, pp. 544-549.
15. A.M. Wennberg, F. Gudmundson, B. Stenquist, A. Ternesten, L. Molne, A. Rosen, et al., In vivo detection of basal cell carcinoma using imaging spectroscopy, Acta Derm. Venereol. 79 (1) (1999) 54-61.
16. M.A. Scott, C. Hooper, A. Sahota, R. Springett, B.W. McIlroy, S.G. Bown, et al., Fluorescence photodiagnosis and photobleaching studies of cancerous lesions using ratio imaging and spectroscopic techniques, Lasers Med. Sci. 15 (2000) 63-72.
17. K.E. Lindeburg, H.M. Brogaard, G.B. Jemec, Pain and photodynamic therapy, Dermatology (Basel, Switzerland) 215 (3) (2007) 206-208. (Pubitemid 47378986)
18. A.M. Wennberg, Pain, pain relief and other practical issues in photodynamic therapy, Australas. J. Dermatol. 46 (2005) S3-S4.
19. C.A. Morton, Photodynamic therapy for nonmelanoma skin cancer - and more?, Arch Dermatol. 140 (1) (2004) 116-120. (Pubitemid 38090279)
20. S. Grapengiesser, M. Ericson, F. Gudmundsson, O. Larko, A. Rosen, A.M. Wennberg, Pain caused by photodynamic therapy of skin cancer, Clin. Exp. Dermatol. 27 (6) (2002) 493-497. (Pubitemid 35278943)
21. C.A. Morton, R.M. MacKie, Photodynamic therapy for Basal Cell Carcinoma: effect of tumour thickness and duration of photosensitizer application on response, Arch. Dermatol. 134 (1998) 248-249.
22. C.A. Morton, C. Whitehurst, J.H. McColl, J.V. Moore, R.M. MacKie, Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma, Arch. Dermatol. 137 (3) (2001) 319-324.
23. M.B. Ericson, C. Sandberg, B. Stenquist, F. Gudmundson, M. Karlsson, A.M. Ros, et al., Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome, Br. J. Dermatol. 151 (6) (2004) 1204-1212.
24. S.R. Wiegell, J. Skiveren, P.A. Philipsen, H.C. Wulf, Pain during photodynamic therapy is associated with protoporphyrin IX fluorescence and fluence rate, Br. J. Dermatol. 158 (4) (2008) 727-733.
25. M.V. Holmes, R.S. Dawe, J. Ferguson, S.H. Ibbotson, A randomized, doubleblind, placebo-controlled study of the efficacy of tetracaine gel (Ametop) for pain relief during topical photodynamic therapy, Br. J. Dermatol. 150 (2) (2004) 337-340.
26. J. Paoli, C. Halldin, M.B. Ericson, A.M. Wennberg, Nerve blocks provide effective pain relief during topical photodynamic therapy for extensive facial actinic keratoses, Clin. Exp. Dermatol. 33 (5) (2008) 559-564.
27. C.B. Halldin, J. Paoli, C. Sandberg, H. Gonzalez, A.M. Wennberg, Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp, Br. J. Dermatol. 160 (4) (2009) 795-800.
28. J. Pagliaro, T. Elliott, M. Bulsara, C. King, C. Vinciullo, Cold air analgesia in photodynamic therapy of basal cell carcinomas and Bowen's disease: an effective addition to treatment: a pilot study, Dermatol. Surg. 30 (1) (2004) 63-66.
29. C. Serra-Guillen, L. Hueso, E. Nagore, M. Vila, B. Llombart, C. Requena Caballero, et al., Comparative study between cold air analgesia and supraorbital and supratrochlear nerve block for the management of pain during photodynamic therapy for actinic keratoses of the frontotemporal zone, Br. J. Dermatol. 161 (2) (2009) 353-356.
30. A. Juzeniene, P. Juzenas, I. Bronshtein, A. Vorobey, J. Moan, The influence of temperature on photodynamic cell killing in vitro with 5-aminolevulinic acid, J. Photochem. Photobiol. B 84 (2) (2006) 161-166.
31. C.M.L. West, J.V. Moore, Cell survival characteristics of a human colon adenocarcinoma cell line after photodynamic treatment: a comparison of Photofrin II and TPPS, Int. J. Radiat. Biol. 54 (4) (1988) 621-634.
32. C.J. Gomer, N. Rucker, A. Ferrario, A.L. Murphree, Expression of potentially lethal damage in Chinese hamster cells exposed to hematoporphyrin derivative photodynamic therapy, Cancer Res. 46 (7) (1986) 3348-3352.
33. J. Moan, T. Christensen, Photodynamic inactivation of cancer cells in vitro. Effect of irradiation temperature and dose fractionation, Cancer Lett. 6 (6) (1979) 331-335.
34. J. Moan, E.O. Pettersen, T. Christensen, The mechanism of photodynamic inactivation of human cells in vitro in the presence of haematoporphyrin, Br. J. Cancer 39 (4) (1979) 398-407.
35. J. Tyrrell, S.M. Campbell, A. Curnow, The validation of a non-invasive fluorescence imaging system to monitor clinical dermatological photodynamic therapy, Photodiagn. Photodyn. Ther. 7 (2010) 86-97.
36. National Institute of Clinical Excellence (NICE), Photodynamic Therapy for Non-melanoma Skin Tumours (Including Premalignant and Primary Nonmetastatic Skin Lesions), Interventional Procedure Guidance, vol. 155, 2006, pp. 1-18.
37. M.D. Abramoff, P.J. Magelhaes, S.J. Ram, Image processing with imageJ, Biophoton. Int. 11 (7) (2004) 36-42.
38. C.E. Thorn, The Regulation of Cutaneous Microvascular Haemodynamics as Determined by Optical Reflectance Spectroscopy; The Role of Vasomotion Exeter: Universities of Exeter and Plymouth, 2008.
39. I.V. Meglinsky, S.J. Matcher, Modelling the sampling volume for skin blood oxygenation measurements, Med. Biol. Eng. Comput. 39 (1) (2001) 44-50.
40. U. Merschbrock, J. Hoffmann, L. Caspary, J. Huber, U. Schmickaly, D.W. Lubbers, Fast wavelength scanning reflectance spectrophotometer for noninvasive determination of hemoglobin oxygenation in human skin, Int. J. Microcirc. Clin. Exp. 14 (5) (1994) 274-281.
41. J. Tyrrell, S.M. Campbell, A. Curnow, The Utilization of a Non-invasive Fluorescence Imaging System to Follow Clinical Dermatological MAL-PDT, International Photodynamic Association: SPIE 2009:73801P.
42. C.A. Morton, S.B. Brown, S. Collins, S. Ibbotson, H. Jenkinson, H. Kurwa, et al., Guidelines for topical photodynamic therapy: report of a workshop of the British photodermatology group, Br. J. Dermatol. 146 (4) (2002) 552-567.
43. M. Ascencio, P. Collinet, M.O. Farine, S. Mordon, Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy, Lasers Surg. Med. 40 (5) (2008) 332-341.
44. J. Tyrrell, S.M. Campbell, A. Curnow, The relationship between protoporphyrin IX photobleaching during real-time dermatological methyl-aminolevulinate photodynamic therapy (MAL-PDT) and subsequent clinical outcome, Lasers Surg. Med. 42 (7) (2010) 613-619.
45. D.J. Robinson, H.S. de Bruijn, N. van der Veen, M.R. Stringer, S.B. Brown, W.M. Star, Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect, Photochem. Photobiol. 67 (1) (1998) 140-149.
46. C.A. Morton, K.E. McKenna, L.E. Rhodes, Guidelines for topical photodynamic therapy: update, Br. J. Dermatol. 159 (6) (2008) 1245-1266.
47. B. Kruijt, H.S. de Bruijn, A. den Heuvel, R.W. de Bruin, H.J. Sterenborg, A. Amelink, et al., Monitoring ALA-induced PpIX photodynamic therapy in the rat esophagus using fluorescence and reflectance spectroscopy, Photochem. Photobiol. 84 (6) (2008) 1515-1527.
48. B.W. McIlroy, T.S. Mann, J.S. Dysart, B.C. Wilson, The effects of oxygenation and photosensitizer substrate binding on the use of fluorescence photobleaching as a dose metric for photodynamic therapy, Vib. Spectrosc. 28 (1) (2002) 25-35.
49. L. Brancaleon, H. Moseley, Effects of photoproducts on the binding properties of protoporphyrin IX to proteins, Biophys. Chem. 96 (1) (2002) 77-87.
50. B. Newell, A.J. Bedlow, S. Cliff, S.B. Drysdale, A.W.B. Stanton, P.S. Mortimer, Comparison of the microvasculature of basal cell carcinoma and actinic keratosis using intravital microscopy and immunohistochemistry, Br. J. Dermatol. 149 (1) (2003) 105-110.
51. A. O'Grady, P. O'Kelly, G.M. Murphy, M. Leader, E. Kay, COX-2 expression correlates with microvessel density in non-melanoma skin cancer from renal transplant recipients and immunocompetent individuals, Hum. Pathol. 35 (12) (2004) 1549-1555.
52. J. Fuchs, J. Thiele, The role of oxygen in cutaneous photodynamic therapy, Free Radical Biol. Med. 24 (5) (1998) 835-847.
53. T.M. Busch, Local physiological changes during photodynamic therapy, Lasers Surg. Med. 38 (5) (2006) 494-499.
54. T.M. Busch, S.M. Hahn, S.M. Evans, C.J. Koch, Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide], Cancer Res. 60 (10) (2000) 2636-2642.
55. B.W. Pogue, J.A. O'Hara, I.A. Goodwin, C.J. Wilmot, G.P. Fournier, A.R. Akay, et al., Tumor PO(2) changes during photodynamic therapy depend upon photosensitizer type and time after injection, Comp. Biochem. Physiol. A Mol. Integr. Physiol. 132 (1) (2002) 177-184.
56. N. Charkoudian, Skin blood flow in adult human thermoregulation: how it works, when it does not, and why, Mayo Clin. Proc. 78 (5) (2003) 603-612.
57. A.P. Castano, P. Mroz, M.R. Hamblin, Photodynamic therapy and anti-tumour immunity, Nat. Rev. Cancer 6 (7) (2006) 535-545.
58. S.O. Gollnick, S.S. Evans, H. Baumann, B. Owczarczak, P. Maier, L. Vaughan, et al., Role of cytokines in photodynamic therapy-induced local and systemic inflammation, Br. J. Cancer 88 (11) (2003) 1772-1779.
59. E. Kabingu, A.R. Oseroff, G.E. Wilding, S.O. Gollnick, Enhanced systemic immune reactivity to a Basal cell carcinoma associated antigen following photodynamic therapy, Clin. Cancer Res. 15 (13) (2009) 4460-4466.